Price$2.04-0.08 (-4.00%)
02:45 PM07:00 PM
News · 26 weeks72-24%
2026-01-182026-07-12
Mix3990d
- Insider22(56%)
- SEC Filings10(26%)
- Other3(8%)
- Leadership2(5%)
- Earnings1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERDirector Phillips Joshua was granted 24,686 shares, increasing direct ownership by 43% to 81,691 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Mirza Mansoor Raza was granted 24,197 shares, increasing direct ownership by 42% to 81,937 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Lawrence Sandra Aj was granted 24,702 shares, increasing direct ownership by 150% to 41,175 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Kamdar Kim P. was granted 25,847 shares, increasing direct ownership by 79% to 58,420 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Critchfield Gregory C was granted 24,020 shares, increasing direct ownership by 3% to 846,886 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Capone Mark Christopher was granted 44,379 shares (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Barlow Jane F was granted 24,375 shares, increasing direct ownership by 107% to 47,088 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- PRPRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE-- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population --SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM® Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions. Because NICU care
- INSIDERSEC Form 3 filed by new insider Capone Mark Christopher3 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- SECSera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORSSALT LAKE CITY, June 30, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Mark Capone will join its Board of Directors, effective July 1, 2026. Mr. Capone is a seasoned healthcare executive with more than 40 years of leadership experience across the diagnostics and life sciences sectors, including extensive service on private and public company boards and committees. In his last operating role, he served as Chief Executive Officer of Myriad Genet
- PRSERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTHSALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced its participation in a multi-institutional research program that was awarded up to $10.4 million by the Advanced Research Projects Agency for Health (ARPA-H) to develop a novel point-of-care diagnostic test designed to improve the safety of labor and delivery. The award, part of ARPA-H's Making Obstetrics Care Smart (MOCS) program, supports a collaboration led by researchers at the University of Califo
- PRSERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY--Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk--SALT LAKE CITY, June 23, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today acknowledged recent legislative action in Illinois aimed at expanding access to evidence-based approaches for identifying and managing the risk of preterm birth among pregnant individuals. The legislation amends the Illinois Public Aid Code to require the state's medical assistance program (Medicaid) to provide coverage and
- INSIDERChief Financial Officer Aerts Austin sold $4,094 worth of shares (2,037 units at $2.01), decreasing direct ownership by 0.67% to 301,190 units (SEC Form 4) (tax withholding)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Commercial Officer Anderson Dyaarl Lee Jr. sold $9,525 worth of shares (4,739 units at $2.01), decreasing direct ownership by 6% to 77,998 units (SEC Form 4) (tax withholding)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERGeneral Counsel Jackson Benjamin sold $4,380 worth of shares (2,179 units at $2.01), decreasing direct ownership by 1% to 161,756 units (SEC Form 4) to satisfy tax liability4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Medical Officer Inglis Tiffany Eul Davis sold $728 worth of shares (362 units at $2.01), decreasing direct ownership by 0.39% to 92,075 units (SEC Form 4) (tax liability)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Executive Officer Lindgardt Zhenya sold $14,050 worth of shares (6,990 units at $2.01), decreasing direct ownership by 0.80% to 865,009 units (SEC Form 4) (tax withholding)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Executive Officer Lindgardt Zhenya sold $43,170 worth of shares (20,755 units at $2.08), decreasing direct ownership by 2% to 871,999 units (SEC Form 4) (withholding obligation)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Financial Officer Aerts Austin sold $11,315 worth of shares (5,440 units at $2.08), decreasing direct ownership by 2% to 303,227 units (SEC Form 4) (tax liability)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Lawrence Sandra Aj sold $3,354 worth of shares (1,560 units at $2.15) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 16,473 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- SECSEC Form 144 filed by Sera Prognostics Inc.144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)
- SECSera Prognostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- INSIDERSEC Form 4 filed by Director Elliott Jeffrey Thomas4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- ANALYSTCraig Hallum initiated coverage on Sera Prognostics with a new price targetCraig Hallum initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $6.00
SERA FAQ
7 questionsWhat does Sera Prognostics Inc. do?
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Where does SERA stock trade?
Sera Prognostics Inc. (SERA) is listed on NASDAQ.What sector and industry is SERA in?
Sera Prognostics Inc. operates in the Health Care sector, Medical Specialities industry.When did Sera Prognostics Inc. go public?
Sera Prognostics Inc. (SERA) completed its IPO in 2021.What are analysts saying about SERA?
Sera Prognostics Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $600.00 price target on 2026-06-04. Recent price targets range from $400.00 to $1900.00.What companies are similar to SERA?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare SERA side-by-side with any of them on Quantisnow.How can I track SERA on Quantisnow?
Quantisnow aggregates Sera Prognostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SERA to receive live email and push alerts on every new disclosure.